FRI0062 Effects of methotrexate and long term low prednisone doses on bone mineral density in patients with early severe rheumatoid arthritis

Background Patients suffering from rheumatoid arthritia (RA) may feature significant loss of bone mineral density (BMD). early aggressive treatment and sometimes low corticosteroids doses are required; however, long term effects on bone are not extensively characterised. Objectives To assess the effects of 10 mg prednisone daily + 7.5 mg methotrexate (MTX) on BMD in patients with early active and severe RA. Methods 32 patients with active RA, with a disease duration less than 2 years, without prior treatment with any disease modifying antirheumatic drugs were randomised to receive either MTX and prednisone or sulphasalazine alone. Osteoporosis treatment was not permitted. Disease activity and BMD were monitored at baseline, 6, 12 and 24 months; BMD was determined by quantitative ultrasound at the calcis bone and was appreciated as broadband ultrasound attenuation (BUA) and quantitative ultrasound index (QUI). BMD loss was calculated in% of baseline. Subgroup analysis (high and low disease activity) was performed upon ESR and CRP values. Results After 6 and 12 months of treatment mean% BUA has decreased significantly (p Conclusion High disease activity is closely associated with bone loss in early active severe RA compared to bone loss due to aggressive therapy including MTX and low doses prednisone.